Amantadine
(Synonyms: 金刚烷胺; 1-Adamantanamine; 1-Aminoadamantane) 目录号 : GC63814
An NMDA receptor antagonist and antiviral agent
Cas No.:768-94-5
Sample solution is provided at 25 µL, 10mM.
Amantadine is an NMDA receptor antagonist with IC50 values of 0.93, 0.82, and 0.47 μM at -70 mV for NR1-1a/NR2A, NR1-1a/NR2B, and NR1-1a/NR2D subunit-containing recombinant receptors, respectively, expressed in HEK293 cells.1 It blocks the influenza A M2 proton channel (IC50 = 16 μM for the recombinant channel expressed in Xenopus oocytes) and inhibits cytotoxicity induced by the influenza A strains H1N1 and H3N2 in MDCK cells (EC50s = 34 and 0.84 μM, respectively).2 It also improves the survival of mice infected with influenza A when administered 24 hours following viral challenge at a dose of 100 mg/kg per day.3 Amantadine (40 mg/kg) decreases dyskinesia induced by L-DOPA in a 6-OHDA hemi-parkinsonian mouse model.4 Formulations containing amantadine have been used in the treatment of various strains of influenza A virus infection and in the treatment of parkinsonism and drug-induced extrapyramidal symptoms.
1.Bresink, I., Benke, T.A., Collett, V.J., et al.Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cellsBr. J. Pharmacol.119(2)195-204(1996) 2.Rey-Carrizo, M., Torres, E., Ma, C., et al.3-Azatetracyclo[5.2.1.15,8.01,5]undecane derivatives: From wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutantJ. Med. Chem.56(22)9265-9274(2013) 3.Smee, D.F., Julander, J.G., Tarbet, E.B., et al.Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agentsAntiviral Res.96(1)13-20(2012) 4.Bido, S., Marti, M., and Morari, M.Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levelsJ. Neurochem.118(6)1043-1055(2011)
Cas No. | 768-94-5 | SDF | Download SDF |
别名 | 金刚烷胺; 1-Adamantanamine; 1-Aminoadamantane | ||
分子式 | C10H17N | 分子量 | 151.25 |
溶解度 | DMSO : 1mg/mL | 储存条件 | 4°C, protect from light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 6.6116 mL | 33.0579 mL | 66.1157 mL |
5 mM | 1.3223 mL | 6.6116 mL | 13.2231 mL |
10 mM | 0.6612 mL | 3.3058 mL | 6.6116 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet